New Issue: ZymoGenetics raises $135 million in upsized follow-on at $18, discounted from $18.39 close

By Ronda Fears

Nashville, Aug. 4 - ZymoGenetics Inc. priced an upsized secondary offering of 7.5 million shares at $18.00 each, discounted from Wednesday's close of $18.39, for gross proceeds of $135 million via sole bookrunner Merrill Lynch & Co.

The issue was boosted from 6.5 million shares.

Seattle-based ZymoGenetics has earmarked proceeds for clinical and preclinical development of existing product candidates, discovery and development of additional product opportunities, capital expenditures and working capital, and other general corporate purposes.

Issuer:	ZymoGenetics Inc.
Issue:	7.5 million shares, up from 6.5 million
Greenshoe:	1,125,000 shares, up from 975,000
Gross proceeds:	$135 million
Price:	$18.00 per share
Bookrunner:	Merrill Lynch & Co.
Co-managers:	Pacific Growth Equities LLC, Bear Stearns & Co. Inc. and Piper Jaffray & Co.
Pricing date:	Aug. 3
Closing date:	Aug. 9
Symbol:	ZGEN

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.